Efficacy of abatacept for IgG4-related disease over 8 months. - Wikidata - awgldk - TriplyDB

Efficacy of abatacept for IgG4-related disease over 8 months.

Efficacy of abatacept for IgG4-related disease over 8 months.

http://www.wikidata.org/entity/Q53757214

about

Recent advances in understanding and managing IgG4-related disease Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series.Diagnostic and treatment workup for IgG4-related disease.A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease.Follicular helper T cells in the pathogenesis of IgG4-related disease.Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies.Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.Response to: 'Could abatacept directly target expanded plasmablasts in IgG4-related disease?' by Alegria et al.Frequency and distribution of CD4+CXCR5+ follicular B helper T cells within involved tissues in IgG4‑related ophthalmic disease.Immunoglobulin G4-related kidney diseases: An updated review.

P2860

Q37664754-7E00D42D-7444-48D9-A807-D71DF6A26AB2 Q37696839-E2805F02-CB15-4FEA-9A0D-D355C79918C8 Q38682216-C0A0A442-00DF-4459-A279-0BFA06773716 Q39009464-1B2CE58F-DB77-4FBB-8E9D-5E3C49FE32D4 Q39275481-F11F0AB9-123F-44D9-A6C1-EB925656F3EB Q39346488-A5D212F1-3092-4478-958F-C24016446627 Q40043818-3BD23282-FBE2-48CA-BB1D-E43BB70FFDAA Q44403879-3DBE0750-C323-4AD6-B620-63A10BF6CB69 Q47641178-3BF2EB52-9102-4894-881A-450E5FC6ADDC Q49279265-462B52C8-5F15-4708-B57F-0C2FCA56CEED

P2860

Efficacy of abatacept for IgG4-related disease over 8 months.

http://www.wikidata.org/entity/Q53757214

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Efficacy of abatacept for IgG4-related disease over 8 months.

@en

Efficacy of abatacept for IgG4-related disease over 8 months.

@nl

type

label

Efficacy of abatacept for IgG4-related disease over 8 months.

@en

Efficacy of abatacept for IgG4-related disease over 8 months.

@nl

prefLabel

Efficacy of abatacept for IgG4-related disease over 8 months.

@en

Efficacy of abatacept for IgG4-related disease over 8 months.

@nl

P1433

Q53757214-4AB01F18-AB68-4B0F-970B-D87952CAA47E

P1476

Q53757214-F0318F8B-0F87-4696-9DBF-6590073F1165

P2093

Q53757214-152FBC6C-B0D1-4A48-8EB2-EEA4D51533D0

Q53757214-1F5E3EC6-30DA-4339-A654-4C8E58D1185B

Q53757214-2EEA7835-1312-44F7-8693-14520DA80E72

Q53757214-36048466-F987-41C6-A319-0038DD96724B

Q53757214-3D138AE3-E0B6-40E4-B330-B1DC40BDC9F7

Q53757214-46D21B83-CE5F-4D2C-8174-C98EFAD39EFF

Q53757214-7DE73527-51EA-460F-85E3-732AF3D148DA

Q53757214-84A79AEE-8A3B-449D-BD38-FFFC47042277

Q53757214-8E4A16E2-02BE-44F4-90DA-C43C4C8625B0

Q53757214-C38522EE-54D8-41E1-8907-AE9463813F28

P2860

Q53757214-26FFB4B5-6AFE-4D16-9570-0F10BEFA457F

Q53757214-2AEA4C5E-A4F0-4348-BC95-A0AF7F21B8B8

Q53757214-3E5DE176-C09B-4278-8A81-E8EF4FAFB6D5

Q53757214-544DA4B0-6E52-4367-BDE3-F5CB4472B0F6

Q53757214-75ED0D14-A058-4233-8CA3-0485D88316D4

P304

Q53757214-A4AA18C7-FA61-4DA4-9542-CA9346F01171

P31

Q53757214-DF02F7F2-DDCD-46FD-9799-EE156F27D2DC

P356

Q53757214-3EDA2CC0-57FB-4139-B7C0-B962796F5CE0

P407

Q53757214-76836AB9-3C60-47D1-9581-A755CF0BC987

P433

Q53757214-94F41FDB-C410-43DD-9C25-0C09CD7C5D60

P478

Q53757214-B6C2242A-1A94-4547-81F5-7DD6830D4926

P577

Q53757214-E645C679-2E81-4225-9BD1-5FEC25E0C578

P5875

Q53757214-59454BD7-F14A-480B-A91F-B2725FCF9298

P698

Q53757214-9D4AB480-E732-4769-9193-5142F82A4C90

P356

ANNRHEUMDIS-2016-209368

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy of abatacept for IgG4-related disease over 8 months.

@en

P2093

Chisako Suzuki

http://www.w3.org/2001/XMLSchema#string

Hidetaka Yajima

http://www.w3.org/2001/XMLSchema#string

Hiroki Takahashi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nakase

http://www.w3.org/2001/XMLSchema#string

Kenichi Takano

http://www.w3.org/2001/XMLSchema#string

Motohisa Yamamoto

http://www.w3.org/2001/XMLSchema#string

Nodoka Sakurai

http://www.w3.org/2001/XMLSchema#string

Teruhito Awakawa

http://www.w3.org/2001/XMLSchema#string

Tetsuo Himi

http://www.w3.org/2001/XMLSchema#string

Yasuyoshi Naishiro

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

Rituximab for IgG4-related disease: a prospective, open-label trial.

Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman's disease.

Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.

P304

1576-1578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2016-209368

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301914018

http://www.w3.org/2001/XMLSchema#string

P698

27147710

http://www.w3.org/2001/XMLSchema#string